Financial writers report on private equity interest in a potential takeover of Bausch & Lomb, with firms like Blackstone and ...

Bausch Health's debt burden and potential bankruptcy risks are mitigated by the likely sale of Bausch + Lomb, which could fetch a premium price. Bausch + Lomb's stable business and the recent ...

NEWS Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb ...

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

Laval, Canada-based Bausch Health announced plans in 2020 to separate Bausch + Lomb into an independent, publicly traded company. The intent was to separate the eye care business, which includes ...

Pucker up and give these nourishing lip balms from brands like Ilia, Charlotte Tilbury, and Glossier a test-drive this winter ...